Suchergebnisse - "Xu, Xu Steven"

PubPharm (7)

1

Clearance as an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies : Circumventing Dose Selection Challenges in Oncology

enthalten in: Clinical pharmacokinetics | 2023

von Chen, C. | Fan, X. | Zhang, L. | +7

2

Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

enthalten in: Clinical and translational science | 2020

von Yan, X. | Xu, X. | Weisel, K. | +11

3

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM) : Clinical and Population Pharmacokinetic Analyses

enthalten in: Advances in therapy | 2020

von Xu, X. | Moreau, P. | Usmani, S. | +13

4

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

enthalten in: Advances in therapy | 2018

von Xu, X. | Dimopoulos, M. | Sonneveld, P. | +13

5

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical pharmacokinetics | 2018

von Yan, X. | Clemens, P. | Puchalski, T. | +15

6

Response to "The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma"

enthalten in: Clinical pharmacology and therapeutics | 2017

von Xu, X. | Schecter, J. | Jansson, R. | +1

CommentOn: Clin Pharmacol Ther. 2017 Jun;101(6):721-724. - PMID 27859027

7

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

enthalten in: Clinical pharmacokinetics | 2017

von Clemens, P. | Yan, X. | Lokhorst, H. | +9

1
[1]